Although not investigated in this study, it could also be hypothesised that with this seismic shift in the glycan profiles in cancer, as well as other disease settings, that Gal-3 and other galectins could be responsible for the resistance of other therapies via enhanced interactions with a range of pro-cancer receptors. The gene discussed is LGALS3; the disease is cancer.